Finally, low subtoxic doses of APE1 inhibitor III (50 nM) added to talazoparib substantially decreased the surviving fraction in 2 MDS (MDS#2, MDS#3), 3 CMML (CMML#2–4), and 7 AML (AML#1, AML#3, AML#5, AML#7, AML#10, AML#11, AML#17) cell samples (Table 1, Figure 2E,F). Here, APEX1 is linked to acute myeloid leukemia.